Previous studies reporting synergistic growth inhibition when combining a FGFR and mTOR or Akt inhibitor in FGFR1-dependent lung, head-and-neck, and hepatocellular carcinoma cell lines28,29 support our findings; however, none of these studies addressed the effectiveness of the drug combinations in relation to EGFR-TKI resistance in NSCLC. The gene discussed is MTOR; the disease is hepatocellular carcinoma.